Press Releases

News Brief

Samsung Biologics to attend BIOPLUS•INTERPHEX KOREA 2024

Samsung Biologics to attend BIOPLUS•INTERPHEX KOREA 2024
Samsung Biologics will be attending BIOPLUSINTERPHEX KOREA 2024 between July 10-12 in Seoul.  


Under the theme, the ‘World’s Most Tangible Bio-Healthcare Convention,’ the event will invite over 250 companies and 10,000 industry experts to share their insights and discuss partnership opportunities.  


Samsung Biologics will highlight its CDMO competitiveness at its booth throughout the convention. The company will share its capacity expansion plans as well as capabilities in diverse modalities, including ADC and mRNA.  


Samsung Biologics is gearing up to provide ADC services, following the completion of its dedicated, standalone facility within this year. In terms of capacity, the company will be able to offer over 1.3 million liters upon the completion of BIO Campus II in 2032.  


Samsung Biologics will also participate in a speaking session, where Heonchang Lim, Director of Formulation Development, will introduce DEVELOPICK™, the company’s robust developability assessment tool.  


Schedule a meeting in advance with the Samsung Biologics team, and learn more about how we can support your development and manufacturing goals: https://partner.samsungbiologics.com/bioplusinterphexkorea2024

Samsung Biologics to attend BIOPLUS•INTERPHEX KOREA 2024
Samsung Biologics will be attending BIOPLUSINTERPHEX KOREA 2024 between July 10-12 in Seoul.  


Under the theme, the ‘World’s Most Tangible Bio-Healthcare Convention,’ the event will invite over 250 companies and 10,000 industry experts to share their insights and discuss partnership opportunities.  


Samsung Biologics will highlight its CDMO competitiveness at its booth throughout the convention. The company will share its capacity expansion plans as well as capabilities in diverse modalities, including ADC and mRNA.  


Samsung Biologics is gearing up to provide ADC services, following the completion of its dedicated, standalone facility within this year. In terms of capacity, the company will be able to offer over 1.3 million liters upon the completion of BIO Campus II in 2032.  


Samsung Biologics will also participate in a speaking session, where Heonchang Lim, Director of Formulation Development, will introduce DEVELOPICK™, the company’s robust developability assessment tool.  


Schedule a meeting in advance with the Samsung Biologics team, and learn more about how we can support your development and manufacturing goals: https://partner.samsungbiologics.com/bioplusinterphexkorea2024

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION